Named entity recognition (NER) — the automatic identification of structured entities such as diseases, drugs, genes, and anatomical locations in free text — is the foundational step in any biomedical knowledge mining pipeline. The temptation to apply a general-purpose NER model, or even a general biomedical model like BioBERT, directly to pharmaceutical or clinical text is strong: these models are freely available, well-documented, and work impressively well on benchmark datasets. They consistently underperform, however, when applied to the specific text types found in pharmaceutical organisations and clinical research settings.
What Makes Clinical and Pharmaceutical Text Different
Several linguistic characteristics of clinical and pharmaceutical text confound general models. Abbreviation density: clinical notes contain acronyms and abbreviations (SOB, CAD, TID, ANCA) that are locally conventional but ambiguous across institutions and contexts. Negation and speculation: a critical proportion of clinical entity mentions are negated ("no evidence of PE") or speculative ("possible early-stage nephropathy") — general NER models often tag these as positive findings, a dangerous error in safety-relevant applications. Drug name variation: proprietary names, international non-proprietary names, chemical names, and informal abbreviations refer to the same compounds; recognising all of them requires a comprehensive synonym dictionary anchored to a pharmaceutical ontology. Nested entities: a phrase like "metformin-induced lactic acidosis" contains three overlapping entities (the drug, the adverse event, and their causal relationship) that simple span-based models handle poorly.
Practical Approaches
The most cost-effective approach for most pharmaceutical knowledge mining projects is to start with a domain-specific pre-trained model (PubMedBERT, BioClinicalBERT, or a recent biomedical LLM), fine-tune it on a small annotated corpus drawn from the actual text type you need to process, and anchor entity recognition to your target ontology's concept identifiers rather than to free-text labels. A fine-tuning corpus of two to five thousand annotated sentences is typically sufficient to substantially improve performance over the baseline model. The annotation effort is not negligible, but it is far smaller than the effort required to build a new model from scratch — and the resulting model is defensible, reproducible, and improvable as more annotated data becomes available.
